title: Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
abstract: Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (≥ 20%) and absolute number (≥ 2 × 10(9)/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL.
authors.affiliation: Amyloidosis and Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain. cfernan1@clinic.ub.es
authors.forename: C
authors.initials: C
authors.lastname: Fernández de Larrea
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: B G M
authors.initials: BG
authors.lastname: Durie
authors.forename: H
authors.initials: H
authors.lastname: Ludwig
authors.forename: S
authors.initials: S
authors.lastname: Usmani
authors.forename: D H
authors.initials: DH
authors.lastname: Vesole
authors.forename: R
authors.initials: R
authors.lastname: Hajek
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: O
authors.initials: O
authors.lastname: Sezer
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.forename: S K
authors.initials: SK
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Mahindra
authors.forename: R
authors.initials: R
authors.lastname: Comenzo
authors.forename: A
authors.initials: A
authors.lastname: Palumbo
authors.forename: A
authors.initials: A
authors.lastname: Mazumber
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
authors.forename: P G
authors.initials: PG
authors.lastname: Richardson
authors.forename: A Z
authors.initials: AZ
authors.lastname: Badros
authors.forename: J
authors.initials: J
authors.lastname: Caers
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: X
authors.initials: X
authors.lastname: LeLeu
authors.forename: M A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: C S
authors.initials: CS
authors.lastname: Chim
authors.forename: R
authors.initials: R
authors.lastname: Schots
authors.forename: A
authors.initials: A
authors.lastname: Noeul
authors.forename: D
authors.initials: D
authors.lastname: Fantl
authors.forename: U-H
authors.initials: UH
authors.lastname: Mellqvist
authors.forename: O
authors.initials: O
authors.lastname: Landgren
authors.forename: A
authors.initials: A
authors.lastname: Chanan-Khan
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: R
authors.initials: R
authors.lastname: Fonseca
authors.forename: G
authors.initials: G
authors.lastname: Merlini
authors.forename: J J
authors.initials: JJ
authors.lastname: Lahuerta
authors.forename: J
authors.initials: J
authors.lastname: Bladé
authors.forename: R Z
authors.initials: RZ
authors.lastname: Orlowski
authors.forename: J J
authors.initials: JJ
authors.lastname: Shah
mesh_terms: D018450:Disease Progression; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged